Screener / SEC EDGAR /CIK 0001822479 /10-K filed Feb 24, 2026, compared with Feb 27, 2025 /Numbers from the XBRL of the 10-Ks
Nasdaq Health care · Health Services

Sotera Health Co SHC

Compare with peers Embed
FY2025 at a glance

Sales up 5.7%, free cash flow up to $149.2M

XBRL, from each 10-K
RevenueStatements
$1.2B from $1.1B in FY2024
FY2019FY2025
Net incomeStatements
$77.9M from $44.4M in FY2024
FY2019FY2025
Free cash flowStatements
$149.2M from $45.1M in FY2024
FY2019FY2025
EPS (diluted)Statements
$0.27 from $0.16 in FY2024
FY2019FY2025
Total debtStatements
$2.1B from $2.2B in FY2024
FY2019FY2025

The latest figures

Price and key numbers

From EDGAR
All key numbers (38)
EPS (ttm)
0.60
Sales (ttm)
1.2B
Net income (ttm)
173.5M
Sales growth
+5.7%
EPS growth
+68.8%
Sales Q/Q
+4.4%
Free cash flow
135.4M
Gross margin
54.6%
Oper. margin
-
Net margin
14.1%
FCF margin
11.0%
ROA
5.1%
R&D / sales
-
Dividend
-
Debt/Eq
2.91
Curr. ratio
3.13
Cash
412.4M
Op. cash flow (ttm)
331.6M
Net debt
1.7B
Quick ratio
2.89
FCF after stock pay
118.3M
Debt / FCF (years)
14.33
Goodwill / assets
33.8%
Tax rate
47.2%
Stock pay / sales
2.7%
Shares out.
285.6M
Shares Y/Y
+0.5%
Book / share
2.57
Cash / share
1.44
Sales / share
4.31
Asset turnover
0.36
Inventory turns
9.53
Days sales out.
44
Sales 3Y CAGR
+5.1%
Sales 5Y CAGR
+7.3%
Employees
3,000
Sales / employee
410K

Hover or tap a number to see the XBRL line item and filing it comes from; click it to open that filing at SEC. What each number means. Looks wrong? Tell us.

Revenue and net income, FY2019 to FY2025

Each fiscal year from its own 10-K · XBRL

Revenue 1.2B +6.9% a year Net income 77.9M
FY2019 revenue 778.3M · RevenueFromContractWithCustomerExcludingAssessedTax, 0001822479-22-000014 FY2019 net income -20.9M · NetIncomeLoss, 0001822479-22-000014 778.3M FY2019 FY2020 revenue 818.2M · RevenueFromContractWithCustomerExcludingAssessedTax, 0001822479-23-000015 FY2020 net income -38.6M · NetIncomeLoss, 0001822479-23-000015 818.2M FY2020 FY2021 revenue 931.5M · RevenueFromContractWithCustomerExcludingAssessedTax, 0001822479-24-000011 FY2021 net income 116.9M · NetIncomeLoss, 0001822479-24-000011 931.5M FY2021 FY2022 revenue 1.0B · RevenueFromContractWithCustomerExcludingAssessedTax, 0001822479-25-000015 FY2022 net income -233.6M · NetIncomeLoss, 0001822479-25-000015 1.0B FY2022 FY2023 revenue 1.0B · RevenueFromContractWithCustomerExcludingAssessedTax, 0001822479-26-000015 FY2023 net income 51.4M · NetIncomeLoss, 0001822479-26-000015 1.0B FY2023 FY2024 revenue 1.1B · RevenueFromContractWithCustomerExcludingAssessedTax, 0001822479-26-000015 FY2024 net income 44.4M · NetIncomeLoss, 0001822479-26-000015 1.1B FY2024 FY2025 revenue 1.2B · RevenueFromContractWithCustomerExcludingAssessedTax, 0001822479-26-000015 FY2025 net income 77.9M · NetIncomeLoss, 0001822479-26-000015 1.2B FY2025

From XBRL in each 10-K. Hover a bar for the line item and filing. "A year" is the steady yearly growth from FY2019 to FY2025 (6 years).

Growth per share, FY2019 to FY2025

Earnings, book value and free cash flow for each diluted share · 10-K XBRL, every year linked to its filing

Average yearly growth
Earnings per share -9.9% a year FY2021 $0.41 to FY2025 $0.27, 4 years
Book value per share +2.1% a year FY2020 $1.90 to FY2025 $2.12, 5 years
Free cash flow per share +4.7% a year FY2019 $0.39 to FY2025 $0.52, 6 years
Fiscal year toEPS (diluted)Book value / shareFree cash flow / share
Dec 31, 2025 $0.27$2.12$0.52
Dec 31, 2024 $0.16$1.42$0.16
Dec 31, 2023 $0.18$1.57-$1.28
Dec 31, 2022 -$0.83$1.25$0.34
Dec 31, 2021 $0.41$2.10$0.64
Dec 31, 2020 -$0.16$1.90$0.28
Dec 31, 2019 -$0.09-$2.76$0.39

Per share means per diluted weighted-average share of the same fiscal year (the count under diluted EPS, put on today's share count after a split). Book value is shareholders' equity at the year end, including any preferred stock; free cash flow is operating cash flow less capital spending. Each tile's rate is the steady yearly growth from the first to the last year it names: the window starts at the oldest year, up to ten years back, with a value above zero.

What the balance sheet holds, per share

Net current asset value and tangible book value, FY2025 · 10-K XBRL, no share price used

Net current asset value, FY2025, in dollars
  • + Current assets $613.4M
  • − All liabilities $2.7B
  • = Net current asset value -$2.0B
Per share, year by year
Tangible book value, FY2025, in dollars
  • + Shareholders' equity $606.0M
  • − Goodwill $1.1B
  • − Other intangible assets $288.2M
  • = Tangible book value -$785.4M
Per share, year by year

Net current asset value is current assets minus all liabilities (the long-term ones too), so it is what would be left from the short-term assets after everything owed is paid; it is blank for a bank, which reports no current assets. Tangible book value is shareholders' equity minus goodwill and other intangible assets; equity includes any preferred stock. Both are divided by the diluted weighted-average share count of the same fiscal year. Red bars are amounts taken off, or a negative result.

SHC against Health care peers

Among the 162 companies, the better end on the right. The band holds the middle half; the line is the median.

Ten years, side by side
Sales growth
+4.8%+20.2%
+5.7%110th of 155 · median +10.5%
Net margin
-4.1%15.3%
14.1%42nd of 154 · median 6.8%
Return on equity
-5.2%18.5%
23.7%23rd of 144 · median 9.2%
Free cash flow margin
2.3%19.2%
11.0%70th of 145 · median 10.0%
Debt / equity (less is better)
1.160.42
2.91102nd of 108 · median 0.69
SHC and the 5 peers closest in revenue
CompanyRevenue (ttm)Sales growthFYGross marginttmNet marginttmROEttmFCF marginttmDebt / equitylatest
SHC Sotera Health Co$1.2B +5.7%54.6%14.1%23.7%11.0%2.91
PGNY Progyny, Inc.$1.3B +10.4%24.9%6.8%22.0%13.4%-
GH Guardant Health, Inc.$1.3B +32.9%65.2%-37.9%--18.2%-
TECH Bio-Techne$1.2B -0.4%65.8%14.0%7.9%25.1%0.18
ACAD Acadia Pharmaceuticals Inc$1.2B +11.9%90.5%30.1%26.1%6.8%-
PBH Prestige Consumer Healthcare Inc.$1.2B -4.3%52.5%13.3%8.0%18.4%1.07
All 162 companies in the group

Where each dollar goes

Revenue through the costs to the net profit, from the 10-K income statement and revenue by product

From $931.5M of sales to $116.9M of profit FY2021

  • Service $805.5M
  • Product $126.0M
Revenue to Gross profit: $518.7MRevenue to Cost of revenue: $412.8MGross profit to Operating profit: $256.7MGross profit to Operating expenses: $261.9MOperating profit to Net profit: $116.9MOperating profit to Tax & other: $139.9M Revenue: $931.5M REVENUE $931.5M +14% Y/Y Gross profit: $518.7M · 56% margin GROSS PROFIT $518.7M 56% margin · +17% Y/Y Cost of revenue: $412.8M · 44% of revenue COST OF REVENUE $412.8M 44% of revenue Operating profit: $256.7M · 28% margin OPERATING PROFIT $256.7M 28% margin · +25% Y/Y Operating expenses: $261.9M · 28% of revenue OPERATING EXPENSES $261.9M 28% of revenue Net profit: $116.9M · 13% margin NET PROFIT $116.9M 13% margin Tax & other: $139.9M · 15% of revenue TAX & OTHER $139.9M 15% of revenue

From $1.0B of sales to $51.4M of profit FY2023

  • Service $905.6M
  • Product $143.7M
Revenue to Gross profit: $577.2MRevenue to Cost of revenue: $472.1MGross profit to Operating profit: $276.7MGross profit to Operating expenses: $300.5MOperating profit to Net profit: $51.4MOperating profit to Tax & other: $225.3M Revenue: $1.0B REVENUE $1.0B +5% Y/Y Gross profit: $577.2M · 55% margin GROSS PROFIT $577.2M 55% margin · +4% Y/Y Cost of revenue: $472.1M · 45% of revenue COST OF REVENUE $472.1M 45% of revenue Operating profit: $276.7M · 26% margin OPERATING PROFIT $276.7M 26% margin · +11% Y/Y Operating expenses: $300.5M · 29% of revenue OPERATING EXPENSES $300.5M 29% of revenue Net profit: $51.4M · 5% margin NET PROFIT $51.4M 5% margin Tax & other: $225.3M · 21% of revenue TAX & OTHER $225.3M 21% of revenue

From $1.1B of sales to $44.4M of profit FY2024

  • Service $941.8M
  • Product $158.6M
Revenue to Gross profit: $602.3MRevenue to Cost of revenue: $498.1MGross profit to Operating profit: $297.6MGross profit to Operating expenses: $304.7MOperating profit to Net profit: $44.4MOperating profit to Tax & other: $253.2M Revenue: $1.1B REVENUE $1.1B +5% Y/Y Gross profit: $602.3M · 55% margin GROSS PROFIT $602.3M 55% margin · +4% Y/Y Cost of revenue: $498.1M · 45% of revenue COST OF REVENUE $498.1M 45% of revenue Operating profit: $297.6M · 27% margin OPERATING PROFIT $297.6M 27% margin · +8% Y/Y Operating expenses: $304.7M · 28% of revenue OPERATING EXPENSES $304.7M 28% of revenue Net profit: $44.4M · 4% margin NET PROFIT $44.4M 4% margin · −14% Y/Y Tax & other: $253.2M · 23% of revenue TAX & OTHER $253.2M 23% of revenue

From $1.2B of sales to $77.9M of profit FY2025

  • Service $995.8M
  • Product $167.9M
Revenue to Gross profit: $645.5MRevenue to Cost of revenue: $518.1MGross profit to Net profit: $77.9MGross profit to Costs, tax, other: $567.6M Revenue: $1.2B REVENUE $1.2B +6% Y/Y Gross profit: $645.5M · 55% margin GROSS PROFIT $645.5M 55% margin · +7% Y/Y Cost of revenue: $518.1M · 45% of revenue COST OF REVENUE $518.1M 45% of revenue Net profit: $77.9M · 7% margin NET PROFIT $77.9M 7% margin · +76% Y/Y Costs, tax, other: $567.6M · 49% of revenue COSTS, TAX, OTHER $567.6M 49% of revenue

Where each $100 of sales went

FY2021
FY2023
FY2024
FY2025
  • Cost of revenue
  • Costs, tax, other
  • Tax & other
  • Net profit

Band widths are the money. Gross profit is revenue less cost of revenue; operating expenses are gross profit less operating profit; R&D is from the income statement and the rest of the operating expenses is everything else; tax includes interest and other items when they are small. Y/Y is the change from the fiscal year before. Revenue by part only for the years in the last two 10-Ks' segment tables. The full income statement

Where the return on equity comes from

DuPont: net margin × asset turnover × leverage, FY2025 against FY2020 · 10-K XBRL, year-end balances

Return on equity 12.9% FY2020: -8.5% net income ÷ equity
Net margin 6.7% FY2020: -4.7% profit per $ of sales: 77.9M ÷ 1.2B
Asset turnover 0.36× FY2020: 0.30× sales per $ of assets: 1.2B ÷ 3.3B
Leverage 5.38× FY2020: 6.10× assets per $ of equity: 3.3B ÷ 606.0M

The three parts multiply to the return on equity. A higher return from leverage alone means more debt or less equity (buybacks shrink equity), not a better business. Year-end balances as filed, not averages, so each number is one line of one 10-K; hover a box for its XBRL tags.

Profitability

  • Net margin above the peer median
    14.1% vs 6.8%
  • Gross margin up over 5 years
    54.2% → 55.5%
  • Return on equity above 15%
    23.7%
  • A profit in 4 of 7 years
Net margin, FY2019 to FY2025: -2.7% to 6.7%

Balance sheet

  • Debt larger than equity
    Debt / equity 2.91 on the latest balance sheet (peer median 0.69)
  • Current assets cover current liabilities
    Current ratio 3.13
  • Net debt over 3 years of free cash flow
    $1.7B net debt, 12.7 years
Debt / equity at each year end, FY2019 to FY2025: 4.03 to 3.53

Cash and shareholders

  • Free cash flow positive in 6 of 7 years
    $149.2M last year
  • Share count up over 5 years
    +20.5%
  • Cash from operations above net income
    $287.2M vs $77.9M
Free cash flow, FY2019 to FY2025: 91.8M to 149.2M

Each tick is a fact with a fixed rule (on /methodology), not a score or advice. A check without the numbers it needs is left out.

$2.2B of principal due, schedule of Dec 31, 2025

Debt

Repayment schedule

From the balance sheet in the latest 10-K or 10-Q (XBRL). When each part falls due, year by year, and the debt note's own lines are on the Debt tab.

Contracted revenue and deferred revenue

Backlog (remaining performance obligations) and cash received in advance, by balance sheet date · XBRL

Contract liabilities, current part

Paid in advance $15.1M cash received before delivery, not yet recognized as revenue, Sep 30, 2026 · +7.6% on a year earlier

Both are balance-sheet-date values from the 10-K and 10-Qs. Backlog is what is under contract, not a forecast: contracts can be cancelled or change in size, and a company counts them in its own way. Hover a number for its XBRL line; click it to open the filing.

Income statement, balance sheet and cash flow

Statements · XBRL, each 10-K and 10-Q

From EDGAR

SHC's income statement, balance sheet and cash flow as reported to the SEC in XBRL, one column per fiscal year, the last 7. Hover a number to see the line item and filing it comes from. Where a company changed how it tags a line, the first tag it reported for that period is used. A number looks wrong? Tell us.

Revenue1.2B
FY2019: 778.3MFY2020: 818.2MFY2021: 931.5MFY2022: 1.0BFY2023: 1.0BFY2024: 1.1BFY2025: 1.2B FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Net income77.9M
FY2019: -20.9MFY2020: -38.6MFY2021: 116.9MFY2022: -233.6MFY2023: 51.4MFY2024: 44.4MFY2025: 77.9M FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Free cash flow149.2M
FY2019: 91.8MFY2020: 67.1MFY2021: 179.4MFY2022: 95.6MFY2023: -362.7MFY2024: 45.1MFY2025: 149.2M FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Free cash flow after stock pay118.3M
FY2019: 84.9MFY2020: 56.1MFY2021: 165.5MFY2022: 74.4MFY2023: -394.9MFY2024: 8.3MFY2025: 118.3M FY2019FY2020FY2021FY2022FY2023FY2024FY2025
EPS (diluted)0.27
FY2019: -0.09FY2020: -0.16FY2021: 0.41FY2022: -0.83FY2023: 0.18FY2024: 0.16FY2025: 0.27 FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Diluted shares286.4M
FY2019: 232.4MFY2020: 237.7MFY2021: 279.4MFY2022: 280.1MFY2023: 283.2MFY2024: 284.9MFY2025: 286.4M FY2019FY2020FY2021FY2022FY2023FY2024FY2025

Revenue by business segment

year to Dec 31, 2025
RevenueSharevs year before
Sterigenics 755.8M65.0% +8.3%
Nelson Labs 220.2M18.9% -3.9%
Nordion 187.6M16.1% +8.2%

10-K 0001822479-26-000015, segment and revenue notes (XBRL).

Revenue by product or service

year to Dec 31, 2025
RevenueSharevs year before
Service 995.8M85.6% +5.7%
Product 167.9M14.4% +5.8%

10-K 0001822479-26-000015, segment and revenue notes (XBRL).

Revenue by region

year to Dec 31, 2025
RevenueSharevs year before
United States 629.5M54.1% +2.1%
Europe 232.2M20.0% +18.5%
Canada 221.9M19.1% +6.3%
Other 79.9M6.9% +1.4%

10-K 0001822479-26-000015, segment and revenue notes (XBRL).

Revenue by business segment, 5 years

from the segment notes of the last 3 10-Ks
FY2021FY2022FY2023FY2024FY2025
Sterigenics571.8M626.6M667.1M697.9M755.8M
Nelson Labs219.1M223.4M221.7M229.2M220.2M
Nordion140.5M153.6M160.5M173.4M187.6M
Sum of segments931.5M1.0B1.0B1.1B1.2B

Operating income by business segment, 5 years

from the segment notes of the last 3 10-Ks
FY2021FY2022FY2023FY2024FY2025
Sterigenics-339.1M362.2M378.2M412.9M
Nordion-89.5M96.7M101.2M107.6M
Nelson Labs-77.6M69.1M69.2M73.3M
Corporate and other-35.3M38.2M43.3M47.2M

Revenue and operating income by business segment, as each 10-K reports them in its segment note (XBRL). Each year comes from the newest 10-K that reports it, so a year the company later recast shows the recast number; click a number to open that 10-K. Rows without a number were not reported as a separate segment that year. "Corporate and other" and "All other" are the 10-K's own lines for what is outside the segments.

Income statement

From EDGAR
FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Revenue778.3M818.2M931.5M1.0B1.0B1.1B1.2B
Cost of revenue382.9M374.6M412.8M446.7M472.1M498.1M518.1M
Gross profit395.4M443.6M518.7M557.0M577.2M602.3M645.5M
SG&A147.5M178.5M198.2M245.7M236.7M242.6M252.8M
Operating income183.6M206.0M256.7M248.3M276.7M297.6M-
Interest expense151.0M211.3M58.8M75.8M173.8M179.9M164.0M
Pretax income-916K-38.9M175.7M-243.1M106.0M113.9M147.5M
Income tax19.5M-1.4M58.6M-9.5M54.7M69.5M69.6M
Net income-20.9M-38.6M116.9M-233.6M51.4M44.4M77.9M
EPS (diluted)-0.09-0.160.41-0.830.180.160.27
Diluted shares232.4M237.7M279.4M280.1M283.2M284.9M286.4M
Depreciation & amortization66.7M63.3M64.2M64.3M76.6M84.3M94.9M
EBITDA250.3M269.3M320.9M312.6M353.3M381.9M-
Gross margin50.8%54.2%55.7%55.5%55.0%54.7%55.5%
Operating margin23.6%25.2%27.6%24.7%26.4%27.0%-
Net margin-2.7%-4.7%12.5%-23.3%4.9%4.0%6.7%
Revenue growth-+5.1%+13.9%+7.8%+4.5%+4.9%+5.7%
EPS growth---to a loss--11.1%+68.8%

Balance sheet

From EDGAR
FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Cash63.0M102.4M106.9M395.2M296.4M277.2M344.6M
Receivables-91.7M108.2M118.5M147.7M140.3M139.3M
Inventory-34.1M54.3M37.1M48.3M49.2M54.4M
Current assets-315.0M346.0M645.0M557.2M526.0M613.4M
Property & equipment-609.8M650.8M774.5M---
Goodwill1.0B1.1B1.1B1.1B1.1B1.1B1.1B
Other intangible assets-643.4M598.8M491.3M416.3M317.7M288.2M
Total assets-2.8B2.8B3.1B3.1B3.1B3.3B
Accounts payable-52.4M72.9M74.1M71.0M55.1M78.0M
Current liabilities-140.6M161.2M791.6M230.7M191.0M249.6M
Total debt-1.8B1.7B1.9B2.2B2.2B2.1B
Total liabilities-2.3B2.2B2.8B2.7B2.7B2.7B
Shareholders' equity-641.1M452.3M586.1M350.2M443.7M404.9M606.0M
Retained earnings--589.1M-472.2M-705.8M-654.4M-610.0M-532.1M

Cash flow

From EDGAR
FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Operating cash flow149.0M120.6M281.5M278.0M-147.7M224.2M287.2M
Capital spending57.3M53.5M102.2M182.4M215.0M179.1M138.0M
Free cash flow91.8M67.1M179.4M95.6M-362.7M45.1M149.2M
Stock-based pay (added back)6.9M11.0M13.9M21.2M32.2M36.8M30.9M
Free cash flow after stock pay84.9M56.1M165.5M74.4M-394.9M8.3M118.3M
Dividends paid691.2M00----
Buybacks034.0M00---
Acquisitions0013.5M00--
Debt raised3.1B150.0M0200.0M500.0M2.3B0
Debt repaid2.6B1.2B100.0M02.5M2.3B86.1M
Investing cash flow-57.3M-158.7M-159.8M-181.9M-214.9M-179.0M-135.1M
Financing cash flow-126.0M73.4M-117.3M197.8M266.0M-50.6M-100.5M

Stock-based pay and leases

From EDGAR
FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Stock-based pay (expense)6.9M11.0M13.9M21.2M32.2M36.8M30.9M
Stock-based pay / revenue0.9%1.3%1.5%2.1%3.1%3.3%2.7%
Operating lease cost-14.4M15.4M15.1M13.9M13.3M13.2M
Operating lease cash paid-12.7M12.5M11.1M10.1M7.4M7.9M
Finance lease principal paid-1.5M901K1.1M1.8M8.1M3.9M
Right-of-use assets-46.0M39.9M26.5M24.0M27.6M33.4M
Operating lease liabilities-48.3M42.3M29.1M26.0M29.5M35.7M
Finance lease liabilities--42.0M58.7M72.6M98.2M97.3M

From SEC's XBRL company facts (data.sec.gov). EBITDA = operating income + depreciation and amortization; free cash flow = operating cash flow - capital spending; total debt = long-term debt (with its current part) + short-term borrowings. Stock-based pay and leases are shown as the company reports them; Tickdelta does not take them out of earnings or add leases to debt. Click a number to open the filing in SEC's Inline XBRL viewer, where you can click the same number to see how it is tagged. Values a company later revised show as revised; the Revised numbers tab lists the changes.

Sources

Every figure is from the company's XBRL filed with each 10-K and 10-Q (data.sec.gov). Hover a number for its line item; click it to open the filing.

Also

Company numbers: the figures the company reports beyond the statements. Peers: ten years, side by side.

Work with it

Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/SHC/export.csv") into a cell.

Next:Peers in numbers
Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.